UNIT 20.5 The TRAMP Mouse as a Model for Prostate Cancer

  1. Arthur A. Hurwitz1,
  2. Barbara A. Foster2,
  3. James P. Allison3,
  4. Norman M. Greenberg4,
  5. Eugene D. Kwon5

Published Online: 1 NOV 2001

DOI: 10.1002/0471142735.im2005s45

Current Protocols in Immunology

Current Protocols in Immunology

How to Cite

Hurwitz, A. A., Foster, B. A., Allison, J. P., Greenberg, N. M. and Kwon, E. 2001. The TRAMP Mouse as a Model for Prostate Cancer. Current Protocols in Immunology. 45:20.5:20.5.1–20.5.23.

Author Information

  1. 1

    SUNY Upstate Medical University, Syracuse, New York

  2. 2

    University of Pittsburgh, Pittsburgh, Pennsylvania

  3. 3

    University of California, Berkeley, Berkeley, California

  4. 4

    Baylor College of Medicine, Houston, Texas

  5. 5

    Loyola University Medical Center, Maywood, Illinois

Publication History

  1. Published Online: 1 NOV 2001
  2. Published Print: OCT 2001


The transgenic adenocarcinoma of the mouse prostate (TRAMP) model closely mirrors the pathogenesis of human prostate cancer. Male TRAMP mice uniformly and spontaneously develop autochthonous (orthotopic) prostate tumors following the onset of puberty. Prostate cancer occurs consequent to the expression of SV40 T antigen. The versatility of the TRAMP model has been extended by establishment of several TRAMP-derived prostate tumor cells lines that can be injected into syngeneic male nontransgenic C57BL/6 hosts to induce ectopic prostate tumorigenesis. Subcutaneous tumor induction using the TRAMP-C cell lines has provided the basis for two additional murine models, the first of which can be used for rapid screening of experimental therapies for the treatment of primary prostate tumors and the second for testing the effectiveness of adjunctive therapies targeting prostate cancer metastases. Detailed descriptions for the harvesting and microdissection of TRAMP prostates and tumors, and the evaluation and scoring of tumors are also provided.